dc.description.abstract | The optimal conditioning for patients with higher risk MDS receiving potentially curative allogeneic haematopoietic stem cell transplant(allo-HCT) remains to be defined. This is particularly the case for patients with excess of blasts at time of allo-HCT. Sequential (Seq) conditioning, whereby chemotherapy is followed rapidly by transplant conditioning, offers an opportunity to decrease disease burden, potentially improving outcomes allo-HCT outcomes. Herein we present the only analysis comparing Seq to myeloablative (MAC) and reduced intensity conditioning (RIC) specifically focussed on MDS patients with excess of blasts at allo-HCT. 303 patients were identified in the EBMT registry, receiving RIC (n = 158), Seq (n = 105), and MAC (n = 40). Median follow-up was 67.2 months and median age at allo-HCT was 59.5 years (IQR 53.5–65.6). For the entire cohort, 3 y overall survival (OS) was 50% (95% CI 45–56%) and relapse free survival (RFS) 45% (95% CI 40–51%). No significant differences in OS (log-rank p = 0.13) and RFS (log-rank p = 0.18) were observed between conditioning protocols. On multivariable analysis, lower performance status, worse IPSS-R cytogenetics, sibling donor (compared to 8/8 MUD) and ?20% blasts at allo-HCT were associated with worse outcomes. In conclusion, the Seq protocol did little to influence the outcome in this high-risk group of patients, with outcomes mostly determined by baseline disease risk and patient characteristics such as performance status. © 2023, The Author(s), under exclusive licence to Springer Nature Limited. | en_US |
dc.department-temp | Potter, V., Kings College Hospital NHS Foundation Trust, London, United Kingdom; Gras, L., EBMT Statistical Unit, Leiden, Netherlands; Koster, L., EBMT Leiden Study Unit, Leiden, Netherlands; Kroger, N., University Hospital Eppendorf, Hamburg, Germany; Sockel, K., Universitaetsklinikum Dresden, Dresden, Germany; Ganser, A., Hannover Medical School, Hannover, Germany; Finke, J., University of Freiburg, Freiburg, Germany; Labussiere-Wallet, H., Centre Hospitalier Lyon Sud, Lyon, France; Peffault de Latour, R., Saint-Louis Hospital, BMT Unit, Paris, France; Koc, Y., Medicana International Hospital Istanbul, Istanbul, Turkey; Salmenniemi, U., HUCH Comprehensive Cancer Center, Helsinki, Finland; Smidstrup Friis, L., Bone Marrow Transplant Unit L, Copenhagen, 4043, Denmark; Jindra, P., Charles University Hospital, Pilsen, Czech Republic; Schroeder, T., University Hospital Essen, Dusseldorf, Germany; Tischer, J., Klinikum Grosshadern, Munich, Germany; Arat, M., Demiroglu Bilim University Istanbul Florence Nightingale Hospital, Stanbul, Turkey; Pascual Cascon, M., Hospital Regional de Málaga, Málaga, Spain; de Wreede, L.C., Leiden University Medical Center, Dept of Biomedical Data Sciences, Leiden, Netherlands; Hayden, P., Department of Haematology, Trinity College Dublin, St. James’s Hospital, Dublin, Ireland; Raj, K., University Colle | en_US |